Ministry of Health of Vietnam, National Institute of Hygiene and Epidemiology of Vietnam. Official Travel Report, Annex 1: IMCI health facility survey in Vietnam; Planning Workshop, Hanoi, June 17–21, 2002. World Health Organization, Western Pacific Regional Office, Reference number MR/2002/0289 (plus personal communication from T. Lambrechts, WHO, on July 1, 2009 and December 9, 2009, which included data summary tables).	-	-	{'abstract': None, 'ids': {'scopus': None, 'pubmed': None, 'doi': '10.1093/heapro/17.4.373', 'embase': None}, 'title': 'National environmental health planning in Vietnam: flying some kites', 'rating': {'authors': 0.0, 'year': 0, 'total': 0.28888888888888886, 'title': 0.4444444444444444}, 'source': 'CrossRef', 'authors': [{'given': 'B.', 'family': 'Powis'}], 'publication_type': {'pagination': '373-381', 'issue': '4', 'title': 'Health Promotion International', 'volume': '17', 'issn': '1460-2245', 'year': 2002, 'cited_medium': None}, 'language': None, 'type': 'journal-article'}
Ministry of Health of Vietnam, National Institute of Hygiene and Epidemiology of Vietnam. Official Travel Report, Annex 1: IMCI health facility survey in Vietnam; Planning Workshop, Hanoi, June 17–21, 2002. World Health Organization, Western Pacific Regional Office, Reference number MR/2002/0289 (plus personal communication from T. Lambrechts, WHO, on July 1, 2009 and December 9, 2009, which included data summary tables).	-	-	{'abstract': 'The World Health Organization will be publishing this AIDS (Acquired Immune Deficiency Syndrome) Information Update for the Western Pacific Region on a quarterly basis and will include the most recent information on the prevalence of AIDS and HIV infections. Depending upon space availability, detailed analysis of the AIDS and HIV infections in addition to pertinent developments in AIDS control in each country will be included in subsequent issues. The 1st case of AIDS in the Region was reported in Australia in 1982. In September 1985, the attention of the WHO Regional Committee for the Western Pacific was drawn to the occurrence of 132 cases of AIDS in 5 countries in the Region -- Australia, 110 cases; New Zealand, 11 cases; Japan, 7 cases; Hong Kong, 3 cases; and China, 1 case. As of November 18, 1987, a cumulative total of 748 cases of AIDS had been reported by 11 countries in the Region, representing a 5-fold increase over the September 1985 figures. In Australia, infection with HIV other than AIDS is a notifiable condition in some states and territories only. A table also indicates the variation in category and in the total surveyed under each category in each country. Another table rearranges this data according to certain risk factors. Results of HIV antibody tests performed on a limited number of homosexuals/bisexuals in Papua New Guinea, the Philippines, and Singapore ranged from around 1/1000 in the Philippines to 20% in Papua New Guinea. Hiv antibody tests performed on a limited number of intravenous drug users in Hong Kong, Macao, and Singapore yielded negative results. It appears that even among prostitutes the proportion of HIV antibody positive reactors continues to be low, ranging from 1-8/10,000 in the Philippines and the Republic of Korea. The proportion of HIV positive reactors among blood donors in 7 countries was quite low indicating that HIV infection has not spread in the general population. The figures indicate that HIV infection rate is low in many countries of the region, indicating it is a relatively new infection, but the danger that it will eventually become widespread is evident.', 'ids': {'scopus': '2-s2.0-0023459690', 'pubmed': '12159119', 'doi': None, 'embase': None}, 'title': 'AIDS information update from WHO Western Pacific Regional Office. November 1987.', 'rating': {'authors': 0.95, 'year': 0, 'total': 0.5329545454545455, 'title': 0.45454545454545453}, 'source': 'Mendeley', 'authors': [{'given': 'W H O', 'family': 'World Health Organization'}, {'given': 'Office', 'family': 'Western Pacific Regional'}], 'publication_type': {'pagination': None, 'issue': None, 'title': 'Virus Information Exchange Newsletter for South-East Asia & the Western Pacific', 'volume': None, 'issn': '08135444', 'year': 1987, 'cited_medium': None}, 'language': None, 'type': 'journal'}
Phua KB, Quak SH, Emmanuel S, Goh PS, Han HH, Hardt K, Bock HL, De Vos B. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine. 2006;24(18):3782-3.	10.1016/j.vaccine.2006.03.040	16600443	{'abstract': None, 'ids': {'scopus': None, 'pubmed': '16600443', 'doi': '10.1016/j.vaccine.2006.03.040', 'embase': None}, 'title': 'A short report on highlights of worldwide development of RIX4414: A Singaporean experience', 'rating': {'authors': 0.9125000000000001, 'year': 1, 'total': 0.978125, 'title': 1.0}, 'source': 'CrossRef', 'authors': [{'given': 'K.B.', 'family': 'Phua'}, {'given': 'S.H.', 'family': 'Quak'}, {'given': 'S.', 'family': 'Emmanuel'}, {'given': 'P.S.C.', 'family': 'Goh'}, {'given': 'H.H.', 'family': 'Han'}, {'given': 'K.', 'family': 'Hardt'}, {'given': 'H.L.', 'family': 'Bock'}, {'given': 'B.', 'family': 'De Vos'}], 'publication_type': {'pagination': '3782-3783', 'issue': '18', 'title': 'Vaccine', 'volume': '24', 'issn': '0264-410X', 'year': 2006, 'cited_medium': None}, 'language': None, 'type': 'journal-article'}
Phua KB, Quak SH, Emmanuel S, Goh PS, Han HH, Hardt K, Bock HL, De Vos B. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine. 2006;24(18):3782-3.	10.1016/j.vaccine.2006.03.040	16600443	{'abstract': 'An unbleached-grade of high alpha pulp could be developed from abaca fiber. The unbleached prehydrolyzed sulfate pulp yield 0.52 percent ash, 0.75 percent lignin, 2.25 percent pentonsans, and 95.05 percent alpha cellulose. Purified by a 3 stage C-E-H bleaching sequence, with a cold extraction stage, prehydrolyzed sulfate pulp of abaca fiber yielded 96.9 percent bleached  pulp, analyzed as 0.06 percent ash, 0 percent lignin, 1.46 percent pentosans and 93.04 percent alpha cellulose. Bleaching developed a viscosity of 6.44 years and a brightness of 86.0 percent. The quality of the purified abaca pulp surpassed the specifications for commercial dissolving pulp.', 'ids': {'scopus': None, 'pubmed': None, 'doi': None, 'embase': None}, 'title': 'High alpha pulp from abaca  (musa Textiles Nee) fibers.', 'rating': {'authors': 0.0, 'year': 1, 'total': 0.23, 'title': 0.2}, 'source': 'Mendeley', 'authors': [{'given': 'B O', 'family': 'Bawagan'}, {'given': 'E M', 'family': 'Midrano'}, {'given': 'E P', 'family': 'Villanueva'}], 'publication_type': {'pagination': None, 'issue': None, 'title': '18', 'volume': None, 'issn': None, 'year': 1972, 'cited_medium': None}, 'language': None, 'type': 'journal'}
Jay SM, Petrilli RM, Ferguson SA, Dawson D, Lamond N. The suitability of a caffeinated energy drink for night-shift workers. Physiology & behavior. 2006;87(5):925-31.	10.1016/j.physbeh.2006.02.012	16574171	{'abstract': None, 'ids': {'scopus': None, 'pubmed': '16574171', 'doi': '10.1016/j.physbeh.2006.02.012', 'embase': None}, 'title': 'The suitability of a caffeinated energy drink for night-shift workers', 'rating': {'authors': 0.9199999999999999, 'year': 0, 'total': 0.88, 'title': 1}, 'source': 'CrossRef', 'authors': [{'given': 'Sarah M.', 'family': 'Jay'}, {'given': 'Renée M.', 'family': 'Petrilli'}, {'given': 'Sally A.', 'family': 'Ferguson'}, {'given': 'Drew', 'family': 'Dawson'}, {'given': 'Nicole', 'family': 'Lamond'}], 'publication_type': {'pagination': '925-931', 'issue': '5', 'title': 'Physiology & Behavior', 'volume': '87', 'issn': '0031-9384', 'year': 2006, 'cited_medium': None}, 'language': None, 'type': 'journal-article'}
Jay SM, Petrilli RM, Ferguson SA, Dawson D, Lamond N. The suitability of a caffeinated energy drink for night-shift workers. Physiology & behavior. 2006;87(5):925-31.	10.1016/j.physbeh.2006.02.012	16574171	{'abstract': "Past research has indicated that caffeinated 'functional energy drinks' (FEDs) are effective in counteracting sleepiness. It is not known however, what impact FEDs have on sleep itself. FEDs contain several active ingredients, including caffeine. They may therefore impact negatively on sleep and hence subsequent performance, deeming their use counterproductive. In a randomised cross-over design, 15 young adults participated in a simulated first night-shift protocol with 2 conditions, Functional Energy Drink (FED) and Non Functional Energy Drink (NonFED). Both involved a period of extended wakefulness (0700-0730 h-24.5 h) followed by an 8-h daytime 'recovery' sleep (0730-1530 h). During the FED condition, a commercially available FED was administered twice during the night. Sleepiness was assessed during the period of extended wakefulness and for a further 6 h after waking. Sleep periods were recorded using a standard 5 channel polysomnogram. Comparison of the sleep periods showed that sleep onset latency remained unchanged as did stage 2 and slow wave sleep. Total sleep time however, was 29.1 min shorter (p < .05) in the FED condition. Sleep efficiency was also significantly reduced from 91.8 ?? .9% to 84.7 ?? 2.7% (p < .05). It is evident that the residual effects of the FED's active ingredients impact on some aspects of daytime sleep following a simulated night-shift. Subsequent performance however was unaffected. The results deem FEDs to be effective for a single night-shift and warrant investigation into their use over successive night-shifts. ?? 2006 Elsevier Inc. All rights reserved.", 'ids': {'scopus': '2-s2.0-33746313649', 'pubmed': '16574171', 'doi': '10.1016/j.physbeh.2006.02.012', 'embase': None}, 'title': 'The suitability of a caffeinated energy drink for night-shift workers', 'rating': {'authors': 0.9199999999999999, 'year': 0, 'total': 0.88, 'title': 1}, 'source': 'Mendeley', 'authors': [{'given': 'Sarah M.', 'family': 'Jay'}, {'given': 'Renée M.', 'family': 'Petrilli'}, {'given': 'Sally A.', 'family': 'Ferguson'}, {'given': 'Drew', 'family': 'Dawson'}, {'given': 'Nicole', 'family': 'Lamond'}], 'publication_type': {'pagination': None, 'issue': None, 'title': 'Physiology and Behavior', 'volume': None, 'issn': '00319384', 'year': 2006, 'cited_medium': None}, 'language': None, 'type': 'journal'}
Seemungal T, Stockley R, Calverley P, Hagan G, Wedzicha JA. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD. 2007;4(3):177-83.	10.1080/15412550701407862	17729060	{'abstract': None, 'ids': {'scopus': None, 'pubmed': '17729060', 'doi': '10.1080/15412550701407862', 'embase': None}, 'title': 'Investigating New Standards for Prophylaxis in Reduction of Exacerbations—The INSPIRE Study Methodology', 'rating': {'authors': 0.9, 'year': 0, 'total': 0.8208333333333333, 'title': 0.9166666666666666}, 'source': 'CrossRef', 'authors': [{'given': 'Terence', 'family': 'Seemungal'}, {'given': 'Robert', 'family': 'Stockley'}, {'given': 'Peter', 'family': 'Calverley'}, {'given': 'Gerry', 'family': 'Hagan'}, {'given': 'Jadwiga A.', 'family': 'Wedzicha'}], 'publication_type': {'pagination': '177-183', 'issue': '3', 'title': 'COPD: Journal of Chronic Obstructive Pulmonary Disease', 'volume': '4', 'issn': '1541-2555', 'year': 2007, 'cited_medium': None}, 'language': None, 'type': 'journal-article'}
Seemungal T, Stockley R, Calverley P, Hagan G, Wedzicha JA. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD. 2007;4(3):177-83.	10.1080/15412550701407862	17729060	{'abstract': "Inflammatory bowel diseases (IBDs; Crohn's disease (CD) and ulcerative colitis) are chronic inflammatory diseases leading to destruction of gastrointestinal tissue. They are characterized by an exaggerated immune response. In CD, an increased expression of T-helper-1 (Th1) cytokines was observed in which interleukin-12 (IL-12) seems to play a pivotal role. Different immunosuppressive agents have been used to treat patients suffering from IBD, nevertheless remarkable side effects or treatment failure are limiting factors in this regard. Therefore, studies on more specific treatment of CD have recently been published, using recombinant anti-inflammatory cytokines or inhibitors of proinflammatory cytokines and their receptors. Beyond these principles anti-IL-12 strategies seem to play a promising role because of the central position of this Th1-inducing cytokine in the inflammatory cascade. Up to now anti-IL-12 antibodies, complement receptor-3 antibodies and IL-12p40 homodimers have been evaluated in their potential to suppress the mucosal inflammation. Based on our understanding of the pathogenesis of CD, the available data and experiences concerning these principles are presented in this review. (Copyright 2003 S. Karger AG, Basel)", 'ids': {'scopus': None, 'pubmed': '12571423', 'doi': None, 'embase': None}, 'title': 'Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease', 'rating': {'authors': 0.4166666666666667, 'year': 0, 'total': 0.2991666666666667, 'title': 0.3}, 'source': 'Mendeley', 'authors': [{'given': 'C', 'family': 'Schmidt'}, {'given': 'T', 'family': 'Marth'}, {'given': 'B M', 'family': 'Wittig'}, {'given': 'A', 'family': 'Hombach'}, {'given': 'H', 'family': 'Abken'}, {'given': 'A', 'family': 'Stallmach'}], 'publication_type': {'pagination': None, 'issue': None, 'title': 'Pathobiology : journal of immunopathology, molecular and cellular biology, 2002-2003, 70(3):177-83', 'volume': None, 'issn': None, 'year': 2002, 'cited_medium': None}, 'language': None, 'type': 'journal'}